In December, Merck signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the closing of the exclusive global ...

The dvm360 editorial team is counting down our Top 20 news stories and articles of the year, from January 1, 2024, to ...

Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...

And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Higher frequency of antibiotic use was not associated with dementia or cognitive impairment; neither was long-term use. No ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture Justice Kyra Harris Bolden ...

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...